



ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions

Arnaud Bourdin¹, Leif Bjermer², Christopher Brightling³, Guy G. Brusselle⁴, Pascal Chanez⁵, Kian Fan Chung⁶, Adnan Custovic⁷, Zuzana Diamant^{8,9}, Sarah Diver¹⁰, Ratko Djukanovic¹¹, Dominique Hamerlijnck ¹², Ildikó Horváth¹³, Sebastian L. Johnston¹⁴, Frank Kanniess¹⁵, Nikos Papadopoulos^{16,17}, Alberto Papi ¹⁸, Richard J. Russell¹⁹, Dermot Ryan ^{20,21}, Konstantinos Samitas²², Thomy Tonia²³, Eleftherios Zervas ²⁴ and Mina Gaga ²⁴

Affiliations: ¹Université de Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France. ²Dept of Respiratory Medicine and Allergy, Lung and Allergy research Unit, Lund, Sweden. ³Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR BRC Respiratory Medicine, University of Leicester, Leicester, UK. ⁴Dept of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium. ⁵University of Marseille, Marseille, France. ⁶National Heart and Lung Institute, Imperial College, London, UK. ⁷Dept of Paediatrics, Imperial College London, London, UK. ⁸Dept of Respiratory Medicine and Allergology, Skane University Hospital, Lund, Sweden. ⁹Respiratory and Allergy Research, QPS Netherlands, The Netherlands. ¹⁰Dept of Respiratory Sciences, College of Life Sciences, Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester, UK. ¹¹University Hospital Southampton NHS Foundation Trust, Southampton, UK. ¹²Amsterdam, The Netherlands. ¹³National Koranyi Institute for Pulmonology, and Dept of Public Health, Semmelweis University, Budapest, Hungary. ¹⁴Dept of Respiratory Medicine, Imperial College London, London, UK. ¹⁵Reinfeld, Germany. ¹⁶Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK. ¹⁷Allergy Dept, 2nd Pediatric Clinic, University of Athens, Athens, Greece. ¹⁸Respiratory Medicine, University of Ferrara, Ferrara, Italy. ¹⁹Institute for Lung Health, NIHR Leicester Biomedical Research Centre, Dept of Infection, Immunity and Inflammation, University of Edinburgh, UK. ²⁰Allergy and Respiratory Research Group, Centre for Population Health Sciences, University of Edinburgh, UK. ²⁰Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. ²⁴7th Respiratory Medicine Dept, Athens Chest Hospital, Athens, Greece.

Correspondence: M. Gaga, Athens Chest Hospital Sotiria, 7th Respiratory Medicine Dept, 152 Mesogion Ave, Athens, 15452, Greece. Email: minagaga@yahoo.com

@ERSpublications

ERS/EAACI statement on severe exacerbations in asthma in adults http://bit.ly/2Hl8sqf

Cite this article as: Bourdin A, Bjermer L, Brightling C, *et al.* ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. *Eur Respir J* 2019; 54: 1900900 [https://doi.org/10.1183/13993003.00900-2019].

This single-page version can be shared freely online.

ABSTRACT Despite the use of effective medications to control asthma, severe exacerbations in asthma are still a major health risk and require urgent action on the part of the patient and physician to prevent serious outcomes such as hospitalisation or death. Moreover, severe exacerbations are associated with substantial healthcare costs and psychological burden, including anxiety and fear for patients and their families. The European Academy of Allergy and Clinical Immunology (EAACI) and the European Respiratory Society (ERS) set up a task force to search for a clear definition of severe exacerbations, and to also define research questions and priorities. The statement includes comments from patients who were members of the task force.